BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development

BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development

October 19, 2007

    PRINCETON, N.J., Oct. 19 /Xinhua-PRNewswire/ -- BioWa,
Inc. (BioWa) announced today that it has entered into a
research agreement which provides GlaxoSmithkline (GSK)
with access to BioWa's patented POTELLIGENT(R) Technology
platform for the development of antibody-dependent cellular
cytotoxicity (ADCC) enhanced antibodies.

    The agreement grants GSK non-exclusive rights to
research and develop antibodies based on POTELLIGENT(R)
Technology for an undisclosed number of targets.  In
return, BioWa will receive an upfront payment, and license
fees.  Other details of the agreement are not disclosed.

    "GSK has long time remained a strong leader in the
pharmaceutical industry for both innovation and
marketing," said Dr. Masamichi Koike, President and
CEO of BioWa.  "With the breadth and depth of GSK
research, we are pleased to partner with a company that has
large capabilities in all sectors of research.  This
collaboration will fulfill BioWa's mission to create
benefit of POTELLIGENT(R) Technology to patients as quickly
as possible."

    About POTELLIGENT(R) Technology 

    POTELLIGENT(R) Technology improves potency and efficacy
of antibody therapeutics, by enhancing antibody-dependent
cellular cytotoxicity (ADCC), one of the major mechanism of
antibody therapeutics.  POTELLIGENT(R) Technology involves
the reduction of the amount of fucose in the carbohydrate
structure of an antibody using a proprietary
fucosyltransferase-knockout CHO cell line as a production
cell.  Research shows that POTELLIGENT(R) Technology
significantly enhances ADCC activity of an antibody in
vitro, thereby increasing the potential for improved
activity in vivo.

    About BioWa, Inc.

    BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo
Co., Ltd., Japan's pharmaceutical and largest biotech
company, and is the exclusive worldwide licensor of
POTELLIGENT(R) Technology, which creates high ADCC
monoclonal antibodies.  Currently, BioWa is developing ADCC
enhanced monoclonal antibody-based therapeutics to fight
cancer and other life-threatening and debilitating diseases
and both BioWa and Kyowa have POTELLIGENT(R) antibody
products in various clinical stages.  BioWa creates and
develops enhanced ADCC antibodies for itself and others,
offering a full range of antibody discovery and development
capabilities.  For more information about BioWa, visit its
web site at www.biowa.com.

    POTELLIGENT(R) is the trademark of Kyowa Hakko Kogyo
Co., Ltd.  All rights are reserved.


    For more information, please contact:

    BioWa, Inc.

     Masamichi Koike, Ph.D, President and CEO
     Phone: [phone]

     Martina Molsbergen, Vice President, Business
Management
     Phone: [phone]